Sun Pharmaceutical Industries

Company overview. Sun Pharmaceutical Industries Ltd. (commonly "Sun Pharma") is an India-based pharmaceutical company founded by Dilip Shanghvi in 1983 and headquartered in Mumbai (the listed entity was incorporated in 1993). It is publicly traded on India's NSE and BSE (NSE: SUNPHARMA; BSE: 524715), with a market capitalization around ₹3.2 trillion (~US$38 billion) per Barron's/FactSet. Sources report trailing-twelve-month revenue of roughly ₹583–585 billion (~US$6.5–6.6 billion) and roughly 29,000 employees (WSJ/MarketWatch/PitchBook), though other published figures range higher.

Products / operations. Sun Pharma describes itself as the world's leading specialty generics company and India's largest drugmaker, with presence in generics, branded specialty, and consumer healthcare across 100+ countries. It manufactures tablets, capsules, injectables, inhalers, ointments, creams, and liquids spanning dermatology, ophthalmology, oncology, CNS, cardiovascular, and diabetes. Its U.S. arm, Sun Pharmaceutical Industries, Inc. (Princeton, NJ), holds hundreds of FDA-approved ANDAs plus branded products such as Ilumya, Leqselvi, Winlevi, and Cequa. The 2015 Ranbaxy acquisition was a defining transaction.

Patent-litigation posture. Sun is an operating company and appears in our database solely as a defendant (1 case; 0 as plaintiff). The tracked suit is a Hatch-Waxman / ANDA patent case brought by branded innovator Novartis against Sun Pharmaceutical Industries Ltd., its U.S. subsidiary, and Sun Pharma Global FZE — a pattern consistent with Sun's role as a large generic filer frequently defending patent challenges. The case sits in the District of Delaware, the standard venue for ANDA litigation, not a plaintiff-friendly outlier.

Notable case / context. The tracked matter, Novartis Pharmaceuticals Corp. v. Sun Pharma Global FZE et al. (D. Del., filed Nov. 2021, terminated April 2023), concerned patents tied to Novartis products including the multiple-sclerosis therapy Gilenya and the dry-eye drug Xiidra (per CourtListener and DrugPatentWatch). Sun had earlier faced related Novartis suits in the same district. As a generics player, Sun also resolves such disputes commercially, e.g., its 2021 Celgene settlement covering generic lenalidomide.